Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo…
Achieve Life Sciences announces board changes By Investing.com Achieve Life Sciences announces board changes…
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a…
Jones Trading sets stock target on Achieve Life Sciences shares By Investing.com Jones Trading sets stock target on Achieve Life Sciences shares…
Achieve Life Sciences secures $60 million in funding By Investing.com Achieve Life Sciences secures $60 million in funding…